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Survey (n12,000), a cross-sectional self-report survey which included the SF-12
Health Survey Version 2 (SF-12v2) to assess HRQoL. Differences between patients
with and without asthma were identified using chi-square tests for categorical
variables and t-tests for continuous variables. Multiple regression was used to
assess the association of asthma with HRQoL while accounting for potential con-
founds, including age, gender, number of co-morbid conditions, possession of pri-
vate insurance, alcohol use, exercise behavior, and cigarette smoking. RESULTS:
Seventy-six percent (n9108) of respondents were familiar with asthma. Physician
diagnosis of asthma was reported by 4% of the sample (n415), and the remaining
96% (n11,585) served as the control group. Asthma patients were younger (36 vs.
41, p0.001), more likely to be female (61% vs. 50%, p.001), have private insurance
(60% vs. 53% p0.01), drink alcohol (68% vs. 60%, p.01), and had more co-morbid
conditions (0.73 vs. 0.32 p0.001). Relative to controls, asthma patients had lower
MCS (42.41 vs. 46.99, p0.001), PCS (47.27 vs. 50.58, p0.001) and SF-6D health
utilities (0.66 vs. 0.73, p0.001). Asthma was associated with significantly lower
HRQoL after adjusting for age, gender, drinking, smoking, exercise, insurance, and
comorbidities, with MCS lower by 2.59 points (p0.001), PCS lower by 3.15 points
(p0.001), and SF-6D lower by 0.05 points (p0.001). CONCLUSIONS: Asthma is
associated with significant HRQoL burden, even after adjusting for covariates. This
analysis may underestimate the burden of asthma, as undiagnosed asthma pa-
tients were likely included in the control group.
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OBJECTIVES: The COPD Assessment Test (CAT) is a short, validated questionnaire
designed to measure the impact that Chronic Obstructive Pulmonary Disease
(COPD) has on the wellbeing and daily life of people living with COPD. The eight
items pertain to COPD symptoms and impact on life, and are rated using a six-point
scale, ranging from zero to five. From its original paper validation, the CAT has
migrated through tomany electronic platforms such as theweb, tablet devices, and
hand-held devices. Usability testing studies have been conducted to test the mi-
gration of the CAT to these platforms. The results have proved that the migration
does not alter the way in which the items are interpreted and how the questions
are completed by peoplewith COPD.More recently, the CAThas been developed for
use as a smart phone app to increase accessibility for people with COPD.
METHODS: A qualitative study was conducted to test the usability of the app with
ten people diagnosed with COPD. Participants completed the CAT using a smart
phone, and were then asked questions that probed on the usability of the ques-
tionnaire as a smart phone app. RESULTS: Due to the CAT being short and concise,
the smart phone app works very well for hosting such a questionnaire. Navigating
around the screen and selecting responses to the questions were completed with
nomajor concerns for half of the patients. Others commented that the app version
could benefit from the functionality of manually increasing the screen size, as this
was not implemented before the usability testingwas conducted, and is a common
feature of smart phones. CONCLUSIONS: Although some further work is still re-
quired before the app is finalised, this study showed that the CAT has great poten-
tial for becoming accessible in many different electronic platforms.
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OBJECTIVES: This study aimed to explore the impact of smoking on quality of life
and productivity in Chronic Obstructive Pulmonary Disease (COPD). METHODS:
Data from the National Health and Wellness Survey (NHWS) were used for this
study. Respondents aged 40 reporting diagnosiswith COPD, chronic bronchitis, or
emphysema in the United States in 2009 and 2010 were included, using 2010 data
for individuals completing the survey in both years. The smoking group included
subjects diagnosed with COPD and who reported currently smoking (n1685). The
former smoker group consisted of those diagnosed with COPD who reported not
smoking in the last 11 years (n1932). Health-related quality of life (HRQoL) was
assessed with the physical (PCS) and mental component summary (MCS) scores
from the SF-12v2, and the SF-6D. The Work Productivity and Activity Impairment
scale (WPAI) assessed productivity, including absenteeism, presenteeism, and
overall work and non-work activity impairment. Multivariate generalized linear
models predicted HRQoL variables using maximum likelihood estimation and an
identity function. This approachwas also used to predict productivity impairment,
with a negative binomial distribution and a log-link function. Covariates included
age, sex, race, insurance status, marital status, income, BMI, alcohol use, exercise,
and asthma diagnosis. RESULTS: The multivariable results showed the following
HRQoL differences between current smokers and former smokers with COPD: MCS
(44.8 vs. 46.7, p0.001), PCS (35.1 vs. 35.8, p0.079), SF-6D (0.63 vs. 0.65, p0.001).
Model results for productivity data estimated the following differences: absentee-
ism (3% vs. 1%, p0.355) presenteeism (23% vs. 18%, p0.010), overall work impair-
ment (25% vs. 21%, p0.043) and activity impairment (52% vs. 49%, p0.004).
CONCLUSIONS: Compared with former smokers quitting 10 years prior, COPD
sufferers currently smoking have poorer MCS scores, equivalent PCS and health
utility scores. They also show similar absenteeism, greater presenteeism and
mildly impaired overall work and activity impairment.
PRS37
EVIDENCES FOR THE DESIGN AND IMPLEMENTATION OF SMOKING CESSATION
INTERVENTIONS IN MEXICO: AN ANALYSIS OF THE WILLINGNESS TO PAY FOR
AN EFFECTIVE METHOD TO QUIT SMOKING
Serván Mori E, Heredia Pi IB, Reynales Shigematsu LM, Bautista Arredondo S
National Institute of Public Health, Cuernavaca, Mexico
OBJECTIVES: To establish the profile of the demand for interventions to quit smok-
ing among smokers inMexico, estimate themaximumwillingness to pay (WTP) for
an effective smoking cessation treatment and to identify smokers’ background,
environmental, demographic, and socioeconomic factors associated with this
valuation.METHODS: From the Global Adult Tobacco Survey in Mexico 2009, there
was selected the sample of analysis constituted by 1626 current smokers. A cross-
sectional study was performed. A statistical association and descriptive analysis
were conducted to describe smokers and their WTP using tobacco-related back-
ground information, environmental, socioeconomic and demographic variables.
RESULTS: 82.2 % of the current smokers who did not want to quit were men,
whereas between those who wanted to quit, 74.9 % were men. In the latter group,
49.8 % of smokers had been consuming tobacco with a daily frequency, for more
than 16 years, 57 % hadmade cessation attempts in the past, and around 10% knew
about the existence of centers to help quit smoking. The WTP for an effective
cessationmethodwas on average $2708Mexican pesos. An increase was identified
in the WTP as the educational level is increased using as reference to the smokers
without formal education. The individuals of the quintiles of socioeconomic status
(SES) 4 and 5 have a major WTP that the individuals of the quintile 1.
CONCLUSIONS: The evidence showed in the present study, will inform and sup-
port policymakers in the design and implementation of smoking cessation inter-
ventions. The study documents the need that these interventions incorporate
components in correspondence with the smokers’ profiles identified to improve
the effectiveness of the interventions to quit smoking, among Mexican smokers.
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OBJECTIVES: Asthma prevalence, morbidity and mortality have continued to in-
crease in the United States over the last decades. Disease management programs
for asthma have become a priority for managed care organizations (MCOs) in order
to optimize the process of care, manage utilization, and improve outcomes. The
objective of this study was to investigate how MCOs currently approach asthma
treatment and management and to identify their biggest challenges and opportu-
nities in improving asthma outcomes, and to determine if publication of revised
asthma guidelines by the National Heart, Lung and Blood Institute (NHLBI) in 2007
changed MCOs’ approach to asthma management. METHODS: A web and paper-
based survey tool was updated from a previous survey whose results were pub-
lished in 2005, and administered to a national sample of 383MCOmedical directors
Descriptive statistics were calculated for all variables. RESULTS: All 61 (15.9%)
responding medical directors collectively serve all regions of the United States,
with almost half servingMedicare and/or Medicaid patients. All directors surveyed
reported that their organizations monitor asthma patients. Plans use a variety of
asthmamanagement activities, including self-management education (80%), edu-
cational materials by mail (70%), general member education (65%) and behavior
modification programs (60%). Most commonly cited factors impeding the provision
of effective asthma carewere noncompliancewith asthma treatment, the inappro-
priate use ofmedications, and the need formultiplemedications. Descriptive com-
parisons show that results are very similar to those from the 2005 survey.
CONCLUSIONS: Survey results show that health plans rely on an array of strategies
to manage asthma patients. Education appears to be an essential part of most
plans’ approaches to disease and cost management. Comparing our results to
those reported in the 2005 study, the 2007 NHLBI guidelines appear to not have
greatly impacted the approach MCO’s take towards asthma management.
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OBJECTIVES: Palavizumab (Synagis) is used in the prevention of seasonal respira-
tory syncytial virus (RSV) infections. The purpose of this study was to assess the
impact of palavizumab use on pneumonia, bronchiolitis and all-cause costs among
children.METHODS:Mississippi Medicaid data for RSV seasons October 1 - March
31 of 2009-2010 and 2010-2011 were used. For each season, pre-term children age 2
years or less at the end of the season were classified as receiving palavizumab or
not. Users and non-users were matched (1:1) on age, gender, race and presence of
chronic lung disease with non-users assigned the index date for the corresponding
palavizumab user. Outcomes included diagnoses of pneumonia or bronchiolitis
within 30 days after the index date and all-cause costs. Costs were compared using
paired t-tests. Conditional logistic regression was used to assess the impact of
palavizumab on prevention of pneumonia and bronchiolitis when controlling for
pre-term stage. RESULTS: In the 2009-2010 season, 337 palavizumab users and 337
non-users were identified. palavizumab users had lower likelihood of diagnoses of
pneumonia (OR: 0.480; 95%CI: 0.213-1.081; p0.08) and bronchiolitis (OR: 0.596; 95%
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